SNBL and Tasso, Inc. Form Joint Venture to Distribute Blood Collection Device in Japan

The latest update is out from Shin Nippon Biomedical Laboratories, Ltd. ( (JP:2395) ).

Shin Nippon Biomedical Laboratories, Ltd. (SNBL) and Tasso, Inc. have announced a joint venture to distribute Tasso’s on-demand blood collection device in Japan. This collaboration aims to enhance self-medication, preventative medicine, and telemedicine in Japan, potentially reducing the burden on medical professionals. While the joint venture’s immediate impact on SNBL’s business performance is minor, it is expected to expand the company’s presence in telemedicine over the medium to long term.

More about Shin Nippon Biomedical Laboratories, Ltd.

Shin Nippon Biomedical Laboratories, Ltd. (SNBL) operates in the biomedical industry, focusing on contract research and translational research services. The company is known for its strong network in the United States and Japan, facilitating collaborations between academia, investors, and professional companies.

YTD Price Performance: -9.17%

Average Trading Volume: 300,490

Technical Sentiment Signal: Hold

Current Market Cap: Yen62.99B

For a thorough assessment of 2395 stock, go to TipRanks’ Stock Analysis page.